Cantor Fitzgerald Estimates PLRX FY2025 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Pliant Therapeutics in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of ($1.51) for the year. Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.64) per share.

Pliant Therapeutics (NASDAQ:PLRX) last posted its earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.17.

PLRX has been the subject of a number of other reports. Needham & Company LLC reissued a “hold” rating and set a $10.00 price target on shares of Pliant Therapeutics in a research report on Tuesday. Citigroup dropped their price target on Pliant Therapeutics from $4.00 to $1.50 and set a “neutral” rating on the stock in a research report on Tuesday. Leerink Partners lowered Pliant Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $33.00 to $2.00 in a research report on Monday. Wells Fargo & Company dropped their target price on Pliant Therapeutics from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Tuesday. Finally, Royal Bank of Canada reduced their price target on Pliant Therapeutics from $4.00 to $3.00 and set a “sector perform” rating for the company in a report on Tuesday. Twelve equities research analysts have rated the stock with a hold rating, According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $13.31.

Pliant Therapeutics Price Performance

PLRX opened at $1.52 on Thursday. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09. The company has a market cap of $92.50 million, a price-to-earnings ratio of -0.46 and a beta of 1.18. The stock has a fifty day simple moving average of $8.60 and a two-hundred day simple moving average of $11.66. Pliant Therapeutics has a 12-month low of $1.26 and a 12-month high of $16.52.

Insiders Place Their Bets

In other news, insider Hans Hull sold 15,936 shares of Pliant Therapeutics stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $178,483.20. Following the transaction, the insider now owns 211,558 shares in the company, valued at $2,369,449.60. This trade represents a 7.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Mike Ouimette sold 10,230 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total value of $112,427.70. Following the completion of the transaction, the general counsel now directly owns 70,544 shares in the company, valued at approximately $775,278.56. This represents a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,855 shares of company stock valued at $1,026,628. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Pliant Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of PLRX. Silverarc Capital Management LLC purchased a new stake in Pliant Therapeutics in the 4th quarter worth approximately $17,326,000. Frazier Life Sciences Management L.P. bought a new position in shares of Pliant Therapeutics during the 4th quarter valued at approximately $14,761,000. Deutsche Bank AG grew its stake in shares of Pliant Therapeutics by 66.3% in the 4th quarter. Deutsche Bank AG now owns 2,551,865 shares of the company’s stock worth $33,608,000 after buying an additional 1,017,500 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Pliant Therapeutics during the fourth quarter worth approximately $8,556,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Pliant Therapeutics by 300.8% in the 4th quarter. JPMorgan Chase & Co. now owns 197,251 shares of the company’s stock valued at $2,598,000 after purchasing an additional 148,039 shares during the last quarter. Hedge funds and other institutional investors own 97.30% of the company’s stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.